FIELD: medicine.
SUBSTANCE: invention relates to field of medicine, namely to cardiology. Displastic syndromes and phenotypes are determined in patients with minor heart anomalies. Medication Atarax is administered in case of myxomatous mitral valve prolapsed MVP, Marfan-like phenotype, syndrome of joint hypermobility and normal QT. Holter ECG monitoring is carried out. If QT interval increases by more than 450 ms on ECG of rest or in Holter ECG monitoring on the second-third day of intake, with duration not less than 0.7% of day monitoring time, latent elongated QT interval is diagnosed. If QT remains lower than 450 ms during entire time of Holter ECG monitoring, norm, absence of latent QT elongation, is diagnosed.
EFFECT: method makes it possible to make diagnostics of QT changes more specific as well as to avoid complications associated with diagnostic intake of adrenalin.
9 tbl, 3 ex, 2 dwg
Title | Year | Author | Number |
---|---|---|---|
AGE-SPECIFIC DIAGNOSTIC TECHNIQUE FOR VARIOUS FORMS OF CONNECTIVE TISSUE DYSPLASIA SYNDROME | 2013 |
|
RU2543166C2 |
METHOD FOR PREDICTION OF HEREDITARY DISORDERS OF CONNECTIVE TISSUE OF HEART | 2019 |
|
RU2707436C1 |
THERAPY OF MITOCHONDRIAL INSUFFICIENCY IN UNDIFFERENTIATED FORMS OF CONNECTIVE TISSUE DYSPLASIA IN CHILDREN | 2006 |
|
RU2379038C2 |
METHOD FOR ANNULOPLASTY OF THE MITRAL VALVE WITH AN AUTOPERICARDIAL STRIP IN PATIENTS WITH DEGENERATIVE DEFECTS OF THE MITRAL VALVE | 2021 |
|
RU2774033C1 |
METHOD FOR PREDICTION OF RISK OF CARDIOVASCULAR DISEASES IN PATIENTS WITH NEUROCIRCULATORY DYSTONIA WITH SIGNS OF CONNECTIVE TISSUE DYSPLASIA | 2014 |
|
RU2597797C2 |
DIAGNOSTIC TECHNIQUE FOR CONNECTIVE TISSUE DYSPLASIA | 2009 |
|
RU2400137C1 |
METHOD FOR DETERMINING THE SEVERITY OF NON-HEREDITARY CONNECTIVE TISSUE DYSPLASIA IN CHILDREN | 2020 |
|
RU2765784C1 |
METHOD OF AGE-SPECIFIC THERAPY AND PREVENTION OF CONNECTIVE TISSUE DYSPLASIA | 2016 |
|
RU2657751C1 |
METHOD FOR PREDICTING MAGNESIUM DEFICIENCY IN CASE OF INTERNAL PATHOLOGY | 2003 |
|
RU2263316C2 |
METHOD OF EFFECTIVE DOSE SELECTION OF BETA-ADRENERGIC BLOCKING AGENTS IN CARDIOMYOPATHIES IN CHILDREN | 2019 |
|
RU2719909C1 |
Authors
Dates
2013-08-10—Published
2012-03-28—Filed